Altered Expression of Alpha 4 Beta 7, a Gut Homing Integrin, by Circulating and Mucosal T Cells in Colonic Mucosal Inflammation
Overview
Affiliations
Background And Aims: Expression of alpha 4 beta 7 on memory T lymphocytes identifies a cell population that preferentially migrates to the gut. Detection of alpha 4 beta 7 on circulating lymphocytes may permit the identification of specific subsets trafficking between the circulation and the gut in inflammatory bowel diseases.
Patients: Samples and clinical details were taken from patients with Crohn's disease (CD), ulcerative colitis (UC), diverticulitis/ infectious colitis, and healthy controls.
Methods: Peripheral blood and lamina propria mononuclear cells were isolated. Cells were labelled with CD3, CD4, CD25, CD45RO or alpha 4 beta 7.
Results: Median levels of circulating total memory T cells (CD4+CD45RO+) were increased in CD (p < 0.01) and UC (p < 0.05). However, the proportion of systemic gut homing T cells (CD4+CD45RO+ alpha 4 beta 7+) was decreased in CD (p < 0.05), UC (p < 0.002), and inflammatory controls (p < 0.05). Levels of activated gut homing T cells (CD4+CD25+ alpha 4 beta 7+) were increased in CD (p < 0.01) and UC (p < 0.05). For both CD4+CD45RO+ and CD4+CD25+ cells, the proportion of lymphocytes coexpressing alpha 4 beta 7 was decreased compared with controls. In small and large intestine lamina propria, expression of alpha 4 beta 7+ on CD3+ cells was extensive, although it was decreased in CD (p < 0.03), UC (p < 0.05), and inflammatory controls (p < 0.05).
Conclusions: Circulating and mucosal gut homing lymphocyte populations are changed in patients with colonic inflammation. This may arise due to a dilution effect from recruited naive T cells, or from integrin down regulation. Changes in general CD4+ lymphocyte populations mask more subtle variations in those cells with gut homing potential.
Yang D, Kim H, Dinh D, Yang J, Hyun C, Jee Y Pediatr Gastroenterol Hepatol Nutr. 2024; 27(6):345-354.
PMID: 39563840 PMC: 11570351. DOI: 10.5223/pghn.2024.27.6.345.
Stutte S, Ishikawa-Ankerhold H, Lynch L, Eickhoff S, Nasiscionyte S, Guo C J Immunol. 2022; 208(6):1445-1455.
PMID: 35181637 PMC: 8919350. DOI: 10.4049/jimmunol.2100022.
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease.
Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N Nat Rev Gastroenterol Hepatol. 2022; 19(6):351-366.
PMID: 35165437 DOI: 10.1038/s41575-021-00574-7.
Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
Gubatan J, Keyashian K, Rubin S, Wang J, Buckman C, Sinha S Clin Exp Gastroenterol. 2021; 14:333-342.
PMID: 34466013 PMC: 8402953. DOI: 10.2147/CEG.S293272.
Shaikh H, Vargas J, Mokhtari Z, Jarick K, Ulbrich M, Pena Mosca J Front Immunol. 2021; 12:689896.
PMID: 34381447 PMC: 8352558. DOI: 10.3389/fimmu.2021.689896.